Opeolu Adeoye1, William A Knight2, Jane Khoury3, Pamela A Schmit4, Heidi Sucharew3, Joseph P Broderick5, Arthur M Pancioli4. 1. University of Cincinnati Neuroscience Institute, Cincinnati, Ohio; Department of Emergency Medicine, University of Cincinnati, Cincinnati, Ohio; Department of Neurosurgery, University of Cincinnati, Cincinnati, Ohio. Electronic address: opeolu.adeoye@uc.edu. 2. University of Cincinnati Neuroscience Institute, Cincinnati, Ohio; Department of Emergency Medicine, University of Cincinnati, Cincinnati, Ohio; Department of Neurosurgery, University of Cincinnati, Cincinnati, Ohio. 3. Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 4. University of Cincinnati Neuroscience Institute, Cincinnati, Ohio; Department of Emergency Medicine, University of Cincinnati, Cincinnati, Ohio. 5. University of Cincinnati Neuroscience Institute, Cincinnati, Ohio; Department of Neurology, University of Cincinnati, Cincinnati, Ohio.
Abstract
BACKGROUND: The Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue Plasminogen Activator (rt-PA) in Acute Ischemic Stroke-Enhanced Regimen (CLEAR-ER) trial found that intravenous rt-PA plus eptifibatide (combination arm) in acute ischemic stroke (AIS) was safe and had a direction of effect that would justify a phase III trial. CLEAR-ER had unanticipated imbalances between treatment groups. We compared the rates of symptomatic intracranial hemorrhage (sICH) and good outcomes for combination therapypatients in the CLEAR-ER trial to a matched cohort of rt-PA patients from the National Institute of Neurological Disorders and Stroke (NINDS) trial. METHODS: CLEAR-ER was a multicenter, double-blind, randomized study; rt-PA-eligible AIS patients were randomized to .6 mg/kg rt-PA plus eptifibatide (135 mcg/kg bolus and .75mcg/kg/min two-hour infusion) versus standard rt-PA (.9 mg/kg). For this analysis, we matched 1:1 CLEAR-ER combination therapypatients with rt-PA arm NINDS trial patients. Patients were matched by age, gender, race, baseline modified Rankin Scale score, baseline National Institutes of Health Stroke Scale (NIHSS) score, and stroke onset to rt-PA time. RESULTS: Fifty-four matches were made. One (1.8%) sICH occurred in each group (odds ratio [OR] 1.00, 95% confidence interval [CI] .01-78.50). At 90 days, 51.8% of the CLEAR-ER group had good outcomes versus 46.3% in the NINDS rt-PA group (OR 1.30, 95% CI .57-2.96). For subjects with baseline NIHSS score > 12 (CLEAR-ER median NIHSS score), 38.5% of the CLEAR-ER group had good outcomes versus 23.1% in the NINDS group (OR 2.33, 95% CI .60-9.02). CONCLUSIONS: The safety and direction of effect of eptifibatide plus rt-PA were confirmed. A phase III trial is needed to determine the efficacy of eptifibatide plus rt-PA for improving long-term outcomes after AIS.
RCT Entities:
BACKGROUND: The Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue Plasminogen Activator (rt-PA) in Acute Ischemic Stroke-Enhanced Regimen (CLEAR-ER) trial found that intravenous rt-PA plus eptifibatide (combination arm) in acute ischemic stroke (AIS) was safe and had a direction of effect that would justify a phase III trial. CLEAR-ER had unanticipated imbalances between treatment groups. We compared the rates of symptomatic intracranial hemorrhage (sICH) and good outcomes for combination therapy patients in the CLEAR-ER trial to a matched cohort of rt-PA patients from the National Institute of Neurological Disorders and Stroke (NINDS) trial. METHODS: CLEAR-ER was a multicenter, double-blind, randomized study; rt-PA-eligible AIS patients were randomized to .6 mg/kg rt-PA plus eptifibatide (135 mcg/kg bolus and .75mcg/kg/min two-hour infusion) versus standard rt-PA (.9 mg/kg). For this analysis, we matched 1:1 CLEAR-ER combination therapy patients with rt-PA arm NINDS trial patients. Patients were matched by age, gender, race, baseline modified Rankin Scale score, baseline National Institutes of Health Stroke Scale (NIHSS) score, and stroke onset to rt-PA time. RESULTS: Fifty-four matches were made. One (1.8%) sICH occurred in each group (odds ratio [OR] 1.00, 95% confidence interval [CI] .01-78.50). At 90 days, 51.8% of the CLEAR-ER group had good outcomes versus 46.3% in the NINDS rt-PA group (OR 1.30, 95% CI .57-2.96). For subjects with baseline NIHSS score > 12 (CLEAR-ER median NIHSS score), 38.5% of the CLEAR-ER group had good outcomes versus 23.1% in the NINDS group (OR 2.33, 95% CI .60-9.02). CONCLUSIONS: The safety and direction of effect of eptifibatide plus rt-PA were confirmed. A phase III trial is needed to determine the efficacy of eptifibatide plus rt-PA for improving long-term outcomes after AIS.
Authors: Arthur M Pancioli; Opeolu Adeoye; Pamela A Schmit; Jane Khoury; Steven R Levine; Thomas A Tomsick; Heidi Sucharew; Claudette E Brooks; Todd J Crocco; Laurie Gutmann; Thomas M Hemmen; Scott E Kasner; Dawn Kleindorfer; William A Knight; Sharyl Martini; James S McKinney; William J Meurer; Brett C Meyer; Alexander Schneider; Phillip A Scott; Sidney Starkman; Steven Warach; Joseph P Broderick Journal: Stroke Date: 2013-07-25 Impact factor: 7.914
Authors: Wade S Smith; Michael H Lev; Joey D English; Erica C Camargo; Maggie Chou; S Claiborne Johnston; Gilberto Gonzalez; Pamela W Schaefer; William P Dillon; Walter J Koroshetz; Karen L Furie Journal: Stroke Date: 2009-10-15 Impact factor: 7.914
Authors: Joseph P Broderick; Yuko Y Palesch; Andrew M Demchuk; Sharon D Yeatts; Pooja Khatri; Michael D Hill; Edward C Jauch; Tudor G Jovin; Bernard Yan; Frank L Silver; Rüdiger von Kummer; Carlos A Molina; Bart M Demaerschalk; Ronald Budzik; Wayne M Clark; Osama O Zaidat; Tim W Malisch; Mayank Goyal; Wouter J Schonewille; Mikael Mazighi; Stefan T Engelter; Craig Anderson; Judith Spilker; Janice Carrozzella; Karla J Ryckborst; L Scott Janis; Renée H Martin; Lydia D Foster; Thomas A Tomsick Journal: N Engl J Med Date: 2013-02-07 Impact factor: 91.245
Authors: Marharyta Kamarova; Sheharyar Baig; Hamish Patel; Kimberley Monks; Mohammed Wasay; Ali Ali; Jessica Redgrave; Arshad Majid; Simon M Bell Journal: Ann Pharmacother Date: 2022-01-29 Impact factor: 3.463
Authors: Ameena Rana; Siyuan Yu; Savina Reid-Herrera; Scott Kamen; Krystal Hunter; Hamza Shaikh; Tudor Jovin; Olga R Thon; Parth Patel; James E Siegler; Jesse M Thon Journal: Front Neurol Date: 2022-09-27 Impact factor: 4.086